Summary
Employers have grappled with soaring demand for GLP-1 drugs such as Ozempic and Wegovy, which can cost thousands of dollars per patient annually.
Bank of America spends $250 million a year on GLP-1 drugs for its employees, CEO says
Source & full coverage: this summary is aggregated from CNBC Finance, the original publisher. Read the complete report for full context, data and quotes.
Read the original report at CNBC Finance →
